BioXyTran is a clinical-stage pharmaceutical company focused on developing innovative platform technologies in Glycovirology and treatments for hypoxia and degenerative diseases. Their Glycovirology platform utilizes carbohydrate drug design to create entry inhibitors that target the binding domains of various viruses, aiming to eliminate viral infections while potentially modulating the immune system. The company’s lead drug candidates, such as ProLectin, are designed to address conditions like COVID-19 and Acute Respiratory Distress Syndrome (ARDS) by binding to viral proteins and facilitating their elimination from the body. This approach is distinct from traditional antiviral therapies, which typically target host cells rather than the virus itself.

In addition to their work in Glycovirology, BioXyTran is developing oxygen therapeutic treatments aimed at addressing hypoxic conditions and preventing tissue necrosis. Their proprietary oxygen transport molecules are designed to enhance the duration and efficacy of oxygen delivery in medical scenarios such as brain strokes and wound healing, where conventional hyperbaric treatments may be limited due to cost and toxicity concerns. The company’s pipeline includes various drug candidates that leverage their patented technologies to improve oxygen supply to tissues, thereby addressing unmet medical needs associated with hypoxia and degenerative diseases.

United States

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

Cardiovascular Diseases

Central Nervous System (CNS)

Infectious Diseases

Nervous System Diseases

BioXyTran

COVID-19

Glycan-based platform therapy/drug`

Biologics

Stroke

BXT-25

Small Molecule Pharmaceuticals

Massachusetts

NanoMedicine/Nanotechnology

Viral Therapies/Virotherapies

Wound Healing

Therapeutic

BioXyTran

Company Details